KR20170082494A - 결정 형태의 글루타미나아제 억제제 - Google Patents

결정 형태의 글루타미나아제 억제제 Download PDF

Info

Publication number
KR20170082494A
KR20170082494A KR1020177006199A KR20177006199A KR20170082494A KR 20170082494 A KR20170082494 A KR 20170082494A KR 1020177006199 A KR1020177006199 A KR 1020177006199A KR 20177006199 A KR20177006199 A KR 20177006199A KR 20170082494 A KR20170082494 A KR 20170082494A
Authority
KR
South Korea
Prior art keywords
cancer
salt
compound
crystalline
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177006199A
Other languages
English (en)
Korean (ko)
Inventor
티모시 에프 스탠턴
제임스 제이 스프링거
재클린 엔 윌리암스
Original Assignee
칼리테라 바이오사이언시즈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 칼리테라 바이오사이언시즈, 인코포레이티드 filed Critical 칼리테라 바이오사이언시즈, 인코포레이티드
Publication of KR20170082494A publication Critical patent/KR20170082494A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020177006199A 2014-08-07 2015-08-07 결정 형태의 글루타미나아제 억제제 Ceased KR20170082494A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462034547P 2014-08-07 2014-08-07
US62/034,547 2014-08-07
PCT/US2015/044301 WO2016022969A1 (en) 2014-08-07 2015-08-07 Crystal forms of glutaminase inhibitors

Publications (1)

Publication Number Publication Date
KR20170082494A true KR20170082494A (ko) 2017-07-14

Family

ID=55264662

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177006199A Ceased KR20170082494A (ko) 2014-08-07 2015-08-07 결정 형태의 글루타미나아제 억제제

Country Status (13)

Country Link
US (2) US10316030B2 (OSRAM)
EP (1) EP3193876B1 (OSRAM)
JP (3) JP6889101B2 (OSRAM)
KR (1) KR20170082494A (OSRAM)
CN (1) CN106999490A (OSRAM)
AU (2) AU2015300825B2 (OSRAM)
BR (1) BR112017002403A2 (OSRAM)
CA (1) CA2957225A1 (OSRAM)
EA (1) EA037738B1 (OSRAM)
IL (1) IL250391B (OSRAM)
MX (1) MX2017001620A (OSRAM)
SG (1) SG11201700816YA (OSRAM)
WO (1) WO2016022969A1 (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS52349B (sr) 2006-09-26 2012-12-31 Celgene Corporation 5-supstituisani derivati hinazolinona kao antitumorski agensi
CA2829570C (en) 2011-03-11 2019-05-07 Celgene Corporation Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
EP2892887B1 (en) 2012-09-04 2020-07-15 Celgene Corporation Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2-6-dione and methods of preparation thereof
ES2899461T3 (es) 2012-11-16 2022-03-11 Calithera Biosciences Inc Inhibidores heterocíclicos de glutaminasa
MX374924B (es) 2014-06-13 2025-03-06 Calithera Biosciences Inc Terapia de combinacion con inhibidores de glutaminasa.
BR112017002403A2 (pt) 2014-08-07 2017-12-05 Calithera Biosciences Inc formas de cristais de inibidores de glutaminase
US20160287564A1 (en) * 2015-03-30 2016-10-06 Calithera Biosciences, Inc. Methods of administering glutaminase inhibitors
CA2981762A1 (en) 2015-04-06 2016-10-13 Calithera Biosciences, Inc. Treatment of lung cancer with inhibitors of glutaminase
CN108601767A (zh) 2015-10-05 2018-09-28 卡利泰拉生物科技公司 用谷氨酰胺酶抑制剂和免疫肿瘤学药剂的组合疗法
JP2019524852A (ja) 2016-08-25 2019-09-05 キャリセラ バイオサイエンシーズ， インコーポレイテッド グルタミナーゼ阻害剤を用いる併用療法
US10278968B2 (en) 2016-08-25 2019-05-07 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
US20210177880A1 (en) * 2017-10-31 2021-06-17 President And Fellows Of Harvard College Methods and compositions for treating acute myeloid leukemia
WO2020194058A1 (en) * 2019-03-26 2020-10-01 Tonix Pharma Holdings Limited Salt forms of s-(n, n-diethylcarbamoyl)glutathione
CN114295836B (zh) * 2021-12-22 2024-12-31 融智生物科技（青岛）有限公司 一种计算设备、存储介质和胶质瘤idh分型检测装置及系统

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1019519A (en) 1911-07-11 1912-03-05 Oscar Martin Polin Apparatus for making backing for teeth.
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
DE69839355T2 (de) 1997-07-29 2009-06-04 Alcon Laboratories, Inc., Fort Worth Ophthalmische Zusammensetzungen enthaltend Galaktomannanpolymere und Borat
US5955476A (en) 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
WO1999038504A1 (en) 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (-)-bupropion
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US6451828B1 (en) 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
WO2002076939A2 (en) 2001-02-05 2002-10-03 Exegenics Inc. Cysteine protease inhibitors
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
DK1654002T4 (da) 2003-08-07 2014-02-17 Allergan Inc Sammensætninger til fremføring af terapeutiske midler til øjnene
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
JP4885122B2 (ja) 2004-04-15 2012-02-29 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 癌、器官傷害、および筋肉リハビリテーション／運動過剰訓練についての診断の生物マーカーとしてのタンパク質分解マーカー
DK2076260T3 (da) 2006-09-15 2011-06-27 Celgene Corp N-methylaminomethyl-isoindol-forbindelser og sammensætninger, der indeholder disse, samt fremgangsmåder til deres anvendelse
JP5561702B2 (ja) 2007-08-02 2014-07-30 アムジエン・インコーポレーテツド Ｐｉ３キナーゼ調節剤および使用方法
US8778410B2 (en) 2008-02-19 2014-07-15 Earnest Medicine Co., Ltd. Oral or enteral composition useful for recovery of physical functions
EP2396313A1 (en) 2009-02-11 2011-12-21 Celgene Corporation Isotopologues of thalidomide
EP2396312A1 (en) 2009-02-11 2011-12-21 Celgene Corporation Isotopologues of lenalidomide
LT3202460T (lt) 2010-02-11 2019-10-10 Celgene Corporation Arilmetoksi izoindolino dariniai ir kompozicijos, apimantys ir jų panaudojimo būdus
WO2011143160A2 (en) 2010-05-10 2011-11-17 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
US10064885B2 (en) 2010-07-09 2018-09-04 Massachusetts Institute Of Technology Metabolic gene, enzyme, and flux targets for cancer therapy
US20120302605A1 (en) 2010-11-18 2012-11-29 Deuteria Pharmaceuticals, Llc 3-deutero-pomalidomide
US9045417B2 (en) 2011-01-14 2015-06-02 Celgene Corporation Isotopologues of isoindole derivatives
CA2742342A1 (en) 2011-02-12 2012-08-12 Baylor Research Institute Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs
FI20115876A0 (fi) 2011-09-06 2011-09-06 Turun Yliopisto Yhdistelmähoito
JP5712882B2 (ja) * 2011-09-28 2015-05-07 株式会社豊田自動織機 電動圧縮機用の電動モータ
CN103030597B (zh) 2011-09-30 2014-10-01 南昌滨西科技有限公司 肾脏型谷氨酰胺酶抑制剂及其制备方法和用途
US8604016B2 (en) * 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
ES2761866T3 (es) * 2011-11-21 2020-05-21 Calithera Biosciences Inc Inhibidores heterocíclicos de glutaminasa
CA2874521A1 (en) 2012-05-24 2013-11-28 Dana-Farber Cancer Institute, Inc. Targeting the glutamine to pyruvate pathway for treatment of oncogenic kras-associated cancer
KR20150054962A (ko) 2012-09-10 2015-05-20 셀진 코포레이션 국소 진행성 유방암의 치료방법
US9618514B2 (en) 2012-09-17 2017-04-11 Agios Pharmaceuticals, Inc Methods of evaluating patients using E-cadherin and vimentin
ES2899461T3 (es) 2012-11-16 2022-03-11 Calithera Biosciences Inc Inhibidores heterocíclicos de glutaminasa
SG11201504022RA (en) 2012-11-21 2015-06-29 Agios Pharmaceuticals Inc Glutamase inhibitors and method of use
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
CN105283182A (zh) 2012-12-03 2016-01-27 卡利泰拉生物科技公司 用谷氨酰胺酶的杂环抑制剂治疗癌症
WO2015061432A1 (en) 2013-10-25 2015-04-30 Calithera Biosciences, Inc. Treatment of viral infections with inhibitors of glutaminase
EP3116872A4 (en) 2014-03-14 2017-08-30 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
US10221459B2 (en) 2014-05-13 2019-03-05 Case Western Reserve University Compositions and methods of treating cancer harboring PIKC3A mutations
MX374924B (es) 2014-06-13 2025-03-06 Calithera Biosciences Inc Terapia de combinacion con inhibidores de glutaminasa.
WO2016004418A1 (en) 2014-07-03 2016-01-07 Board Of Regents, University Of Texas System Glutaminase inhibitor therapy
WO2016014890A1 (en) 2014-07-24 2016-01-28 Calithera Biosciences, Inc. Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase
BR112017002403A2 (pt) 2014-08-07 2017-12-05 Calithera Biosciences Inc formas de cristais de inibidores de glutaminase
US10245254B2 (en) 2014-10-03 2019-04-02 University of Pittsburgh—of the Commonwealth System of Higher Education Glutaminase inhibitors
WO2016077632A2 (en) 2014-11-13 2016-05-19 Buck Institute For Research On Aging Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications
US20160287564A1 (en) 2015-03-30 2016-10-06 Calithera Biosciences, Inc. Methods of administering glutaminase inhibitors
CA2981762A1 (en) 2015-04-06 2016-10-13 Calithera Biosciences, Inc. Treatment of lung cancer with inhibitors of glutaminase
CN108601767A (zh) 2015-10-05 2018-09-28 卡利泰拉生物科技公司 用谷氨酰胺酶抑制剂和免疫肿瘤学药剂的组合疗法
US10278968B2 (en) 2016-08-25 2019-05-07 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
JP2019524852A (ja) 2016-08-25 2019-09-05 キャリセラ バイオサイエンシーズ， インコーポレイテッド グルタミナーゼ阻害剤を用いる併用療法
US20180055825A1 (en) 2016-08-25 2018-03-01 Yu Liang Treatment of cancer with inhibitors of glutaminase
JP2020510032A (ja) 2017-03-10 2020-04-02 キャリセラ バイオサイエンシーズ， インコーポレイテッド グルタミナーゼ阻害剤との併用療法

Also Published As

Publication number Publication date
JP2017523991A (ja) 2017-08-24
US20170226101A1 (en) 2017-08-10
JP6889101B2 (ja) 2021-06-18
AU2015300825B2 (en) 2019-10-10
EP3193876A1 (en) 2017-07-26
BR112017002403A2 (pt) 2017-12-05
SG11201700816YA (en) 2017-02-27
JP2021165286A (ja) 2021-10-14
CN106999490A (zh) 2017-08-01
EP3193876A4 (en) 2017-12-27
JP2020037588A (ja) 2020-03-12
EA037738B1 (ru) 2021-05-17
US20190359607A1 (en) 2019-11-28
AU2015300825A1 (en) 2017-03-09
CA2957225A1 (en) 2016-02-11
MX2017001620A (es) 2017-05-10
WO2016022969A1 (en) 2016-02-11
AU2019284149A1 (en) 2020-01-30
US10676472B2 (en) 2020-06-09
EA201790337A1 (ru) 2017-09-29
US10316030B2 (en) 2019-06-11
IL250391B (en) 2021-10-31
IL250391A0 (en) 2017-03-30
EP3193876B1 (en) 2022-01-12

Similar Documents

Publication Publication Date Title
US10676472B2 (en) Crystal forms of glutaminase inhibitors
KR102220175B1 (ko) 헤테로사이클릭 글루타미나아제 억제제
JP2023078375A (ja) Ｓ１ｐ１活性を調節するための化合物およびその使用法
TW202019900A (zh) Ptpn11抑制劑
JP2018520352A (ja) アルギナーゼ活性を阻害するための組成物および方法
CN111201223A (zh) SHP2的八氢环戊二烯并[c]吡咯别构抑制剂
JP2021501145A (ja) 血液学的障害を治療するための化合物および組成物
US11826363B2 (en) Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient
KR20170132333A (ko) 글루타미나제 억제제에 의한 폐암의 치료
TW200916458A (en) Heterocyclic compounds and methods of use thereof
JP2023109937A (ja) ３－置換１，２，４－オキサジアゾールの結晶形態
KR20190040302A (ko) 글루타미나제 억제제와의 병용 요법
JP2019534865A (ja) クロモボックスタンパク質阻害剤およびその使用
JP2018514557A (ja) Ｓｔａｔ３経路阻害薬およびキナーゼ阻害薬を用いて癌を治療するための方法
WO2016196890A1 (en) Inhibitors of hexokinase and methods of use thereof
WO2011095807A1 (en) Combinations of mek and hh inhibitors
WO2018009539A1 (en) Inhibitors of hexokinase and methods of use thereof
US20250042918A1 (en) Compounds
HK1241722A1 (en) Crystal forms of glutaminase inhibitors
CN110612290A (zh) 新的苯并咪唑酮化合物和其医药用途
HK40031549B (zh) 用於治疗血液病的化合物和组合物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170306

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200728

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220527

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220803

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220527

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I